LO-PHARMA
ActiveSummary
LO-PHARMA has been active since 2008 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €79,136 and a net result of -€15,388. Equity is growing by about 20% per year across the filed financial years. Its solvency ranks better than 24% of 12,578 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.6% (low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
02-07
NBB filing
Annual accounts filed
financial year 2025 · abbreviated format
2025
21-08
NBB filing
Annual accounts filed
financial year 2024 · abbreviated format · 21 days late
2024
29-08
NBB filing
Annual accounts filed
financial year 2023 · abbreviated format · 29 days late
2023
03-07
NBB filing
Annual accounts filed
financial year 2022 · abbreviated format
2022
08-08
NBB filing
Annual accounts filed
financial year 2021 · abbreviated format · 8 days late
2021
31-12
Financial
Highest result from 2018 to 2025net €36,359 ▲0%
Operating result €60,753, net result €36,359, both a record.
01-07
NBB filing
Annual accounts filed
financial year 2020 · abbreviated format
2020
08-09
NBB filing
Annual accounts filed
financial year 2019 · abbreviated format · 39 days late
2019
31-12
Financial
Back to profitnet €12,558
Net result €12,558 after one loss-making year.
19-07
NBB filing
Annual accounts filed
financial year 2018 · abbreviated format
2018
13-08
NBB filing
Annual accounts filed
financial year 2017 · abbreviated format · 13 days late
2017
08-06
NBB filing
Annual accounts filed
financial year 2016 · abbreviated format
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.Of the 16 annual accounts filed, the latest 10 are here; all 16 are under Financials.
0 of 2 deeds read
About the unread acts
We know of 2 Belgian Official Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.